NovaBay Pharmaceuticals Inc (NBY)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014329)
◆英語タイトル:NovaBay Pharmaceuticals Inc (NBY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014329
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:59
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that develops eyecare products. The company’s products include daily lid and lash hygiene spray solution, skin and wound cleanser, and cosetic procedures. Its daily lid and lash hygiene spray solution helps in removal of foreign materials including microorganisms and debris on and around the lid and eyelid margins. NovaBay develops aganocide compound through research and development based on the human body’s natural immune system and molecules involved in combating infections.The company’s products finds application in various therapeutic areas such as wound care, dermatology, ophthalmology, and neutrophase. It partners with pharmaceutical and biotech companies. NovaBay is headquartered in Emeryville, California, the US.

NovaBay Pharmaceuticals Inc (NBY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
NovaBay Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
ALPHAEON Enters into Agreement with NovaBay Pharma 13
NovaBay Pharma Enters into Distribution Agreement with Cardinal Health for Avenova 14
NovaBay Pharma Enters into Distribution Agreement with Biopharm for NeutroPhase 15
Licensing Agreements 16
NovaBay Pharma Enters Into Licensing Agreement With China Pioneer Pharma For CelleRx And i-Lid Cleanser 16
Shin Poong Enters Into Licensing Agreement With NovaBay For NeutroPhase 17
Equity Offering 18
NovaBay Pharma Raises USD0.9 Million in Private Placement of Shares upon Exercise of Warrants 18
NovaBay Pharma Raises USD7 Million in Private Placement of Shares upon Exercise of Warrants 19
NovaBay Pharma Raises USD6.9 Million in Private Placement of Shares upon Exercise of Warrants 20
NovaBay Pharma Raises USD4 Million in Second and Final Tranche of Private Placement of Units 21
NovaBay Pharma Raises USD7.8 Million in First Tranche of Private Placement of Units 22
NovaBay Pharma Raises USD2.8 Million in Private Placement of Shares 23
NovaBay Pharma Raises USD2.5 Million in Public Offering of Shares 24
NovaBay Pharma Raises USD6.9 Million in Private Placement of Shares and Warrants 26
NovaBay Pharma Raises USD4.7 Million in Private Placement of Units 27
NovaBay Pharma Raises USD6.7 Million in Public Offering of Units 28
NovaBay Pharma Completes Public Offering Of Shares For US$7 Million 29
NovaBay Pharma Completes Registered Direct Offering Of US$5.16 Million 30
Acquisition 32
Jinzi Ham to Acquire 37.14% Stake in NovaBay Pharma for USD27.06 Million 32
NovaBay Pharmaceuticals Inc – Key Competitors 33
NovaBay Pharmaceuticals Inc – Key Employees 34
NovaBay Pharmaceuticals Inc – Locations And Subsidiaries 35
Head Office 35
Recent Developments 36
Financial Announcements 36
Nov 14, 2017: NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results 36
Aug 10, 2017: NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results 38
May 11, 2017: NovaBay Pharmaceuticals Reports First Quarter 2017 Financial Results 40
Mar 23, 2017: NovaBay Pharmaceuticals Reports 2016 Full Year and Fourth Quarter Financial Results and Provides 2017 Financial Guidance 42
Jan 09, 2017: Novabay Pharmaceuticals Announces Preliminary Sales For The Fourth Quarter Of 2016 44
Nov 10, 2016: NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results 45
Aug 11, 2016: NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results 47
May 12, 2016: NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results 49
Mar 03, 2016: NovaBay Pharmaceuticals Reports 2015 Fourth Quarter and Full Year Financial Results 51
Corporate Communications 53
Jul 10, 2017: NovaBay Pharmaceuticals Announces CFO Transition 53
Oct 31, 2016: NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements 54
Jun 13, 2016: NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer 55
May 09, 2016: NovaBay Pharmaceuticals Appoints Todd Zavodnick to its Board of Directors 56
Other Significant Developments 57
Jan 11, 2016: NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million 57
Jan 07, 2016: NovaBay Pharmaceuticals Secures $3 Million Bridge Loan 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
NovaBay Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
NovaBay Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
NovaBay Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
ALPHAEON Enters into Agreement with NovaBay Pharma 13
NovaBay Pharma Enters into Distribution Agreement with Cardinal Health for Avenova 14
NovaBay Pharma Enters into Distribution Agreement with Biopharm for NeutroPhase 15
NovaBay Pharma Enters Into Licensing Agreement With China Pioneer Pharma For CelleRx And i-Lid Cleanser 16
Shin Poong Enters Into Licensing Agreement With NovaBay For NeutroPhase 17
NovaBay Pharma Raises USD0.9 Million in Private Placement of Shares upon Exercise of Warrants 18
NovaBay Pharma Raises USD7 Million in Private Placement of Shares upon Exercise of Warrants 19
NovaBay Pharma Raises USD6.9 Million in Private Placement of Shares upon Exercise of Warrants 20
NovaBay Pharma Raises USD4 Million in Second and Final Tranche of Private Placement of Units 21
NovaBay Pharma Raises USD7.8 Million in First Tranche of Private Placement of Units 22
NovaBay Pharma Raises USD2.8 Million in Private Placement of Shares 23
NovaBay Pharma Raises USD2.5 Million in Public Offering of Shares 24
NovaBay Pharma Raises USD6.9 Million in Private Placement of Shares and Warrants 26
NovaBay Pharma Raises USD4.7 Million in Private Placement of Units 27
NovaBay Pharma Raises USD6.7 Million in Public Offering of Units 28
NovaBay Pharma Completes Public Offering Of Shares For US$7 Million 29
NovaBay Pharma Completes Registered Direct Offering Of US$5.16 Million 30
Jinzi Ham to Acquire 37.14% Stake in NovaBay Pharma for USD27.06 Million 32
NovaBay Pharmaceuticals Inc, Key Competitors 33
NovaBay Pharmaceuticals Inc, Key Employees 34

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ NovaBay Pharmaceuticals Inc (NBY)-製薬・医療分野:企業M&A・提携分析(NovaBay Pharmaceuticals Inc (NBY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆